Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT03576612 : GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas
PhasePhase 1
AgesMin: 18 Years Max: N/A
Inclusion Criteria:

- Patients must have operable brain tumor presumed to be high grade glioma (HGG) based
on clinical and radiologic evaluation, where a gross total surgical resection of the
contrast-enhancing area is intended; pathologic confirmation of HGG must be made at
the time of surgery prior to AdV-tk injection, if not previously determined

- Patients must have a Karnofsky performance status >= 70% (i.e. the patient must be
able to care for himself/herself with occasional help from others)

- Absolute neutrophil count >= 1,500/uL

- Platelets >= 100,000/uL

- Hemoglobin >= 9 g/dL

- Total bilirubin =< 1.5 x institutional upper limit of normal (ULN), (except for
patients with known Gilbert's syndrome who must have normal direct bilirubin)

- Aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase
(SGOT)/alanine aminotransaminase (ALT) serum glutamate pyruvate transaminase (SGPT) =<
3.0 x institutional ULN

- Creatinine =< institutional ULN

- Calculated creatinine clearance >= 40 ml/min (use a modified Cockcroft-Gault equation)

- Activated partial thromboplastin time/partial thromboplastin time (APTT/PTT) =< 1.5 x
institutional ULN

- Patients must be able to provide written informed consent

- Patients must have magnetic resonance imaging (MRI) within 14 days of starting
treatment; patients must be able to tolerate MRI

- Women of childbearing potential must agree to have a negative serum pregnancy test
within 24 hours prior to treatment start; women of childbearing potential must agree
to use adequate contraception (hormonal or barrier method of birth control;
abstinence) prior to study entry, for the duration of study treatment, and through at
least 5 months after the last dose of study drug; should a woman become pregnant or
suspect she is pregnant while participating in this study, she should inform her
treating physician immediately; sexually active men of reproductive potential who are
partners of women with reproductive potential must also agree to use adequate
contraception prior to the study, for the duration of study participation, and through
at least 7 months after the last dose of study drug; adequate methods of effective
birth control include sexual abstinence (men, women); vasectomy; or a condom with
spermicide (men) in combination with barrier methods, hormonal birth control or
intrauterine device (IUD) (women)

- Patients must have no concurrent malignancy except curatively treated basal or
squamous cell carcinoma of the skin or carcinoma in situ of the cervix, breast, or
bladder; patients with prior malignancies must be disease-free for >= two years;
patients with low-risk prostate cancer on active surveillance are eligible

- Patients must be able to swallow oral medications

- Patients must not have received prior radiation therapy, chemotherapy, immunotherapy
or therapy with biologic agent (including immunotoxins, immunoconjugates, antisense,
peptide receptor antagonists, interferons, interleukins, tumor infiltrating lymphocyte
[TIL], lymphokine-activated killer [LAK] or gene therapy), or hormonal therapy for
their brain tumor; glucocorticoid therapy is allowed

Exclusion Criteria:

- Patients receiving any other investigational agents are ineligible

- Patients with a history of hypersensitivity or allergic reactions attributed to
compounds of similar chemical or biologic composition to valacyclovir, acyclovir, or
temozolomide are ineligible; the valacyclovir and temozolomide package inserts can be
referenced for more information

- Patients with a history of severe hypersensitivity reaction to any monoclonal antibody
are ineligible

- Patients who require therapy with systemic immunosuppressive drugs except
corticosteroids are ineligible

- Patients with a history of active autoimmune disease requiring treatment in the past 2
years are ineligible

- Patients with uncontrolled intercurrent illness including, but not limited to, ongoing
or active infection, symptomatic congestive heart failure, unstable angina pectoris,
cardiac arrhythmia, active liver disease or active hepatitis, or psychiatric
illness/social situations that would limit compliance with study requirements, are

- Pregnant women are excluded from this study; breastfeeding should be discontinued if
the mother is treated with these agents through 1 week after receiving the last dose
of study drugs

- Patients who are known to be human immunodeficiency virus (HIV) positive are
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557